Expression of concern
Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas
Paper Information
Record ID:
36297
Author(s):
Publication Date:
February 13, 2008
Retraction Date:
March 25, 2022
(3.7 years years ago)
Subjects:
Institutions:
Country:
🇮🇹 ItalyArticle Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Expression of concern Details
Retraction Reasons:
Nature of Retraction:
Expression of concern
Retraction Notice:
10.1371/journal.pone.0266300Citations (53)
53
Total Citations2
Post-Retraction(3.8%)
49
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
1
Within 1 year
1
After 2+ years
913
Days since retraction (latest)
Paper citing Induction of ErbB-3 Expression by α6β4 Integrin Co...
Unknown Authors
Unknown Journal
Published: Unknown
Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin
Shih‐Yao Chen, Chung-Teng Wang, Tang‐Hsiu Huang et al. (10 authors)
Cells
Open Access
Published: Sep 2024
1 citation
1 citation
913 days after retraction
Epigenetic factors in breast cancer therapy
Runjhun Mathur, Niraj Kumar Jha, Gaurav Saini et al. (13 authors)
Frontiers in Genetics
Open Access
Published: Sep 2022
6 citations
6 citations
182 days after retraction
Expression of Concern: Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas
Unknown Authors
PLoS ONE
Open Access
Published: Mar 2022
Same day as retraction
RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence
Joseph L. Regan, Dirk Schumacher, Stephanie Staudte et al. (15 authors)
iScience
Open Access
Published: May 2021
12 citations
12 citations
305 days before retraction
RNA-Sequencing of Long-Term Label-Retaining Colon Cancer Stem Cells Identifies Novel Regulators of Quiescence
Joseph L. Regan, Dirk Schumacher, Stephanie Staudte et al. (15 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Feb 2021
416 days before retraction
Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes
Nicole Mavingire, P. Campbell, Jonathan Wooten et al. (7 authors)
Cancer Letters
Open Access
Published: Dec 2020
11 citations
11 citations
471 days before retraction
Cell signaling and cancer: a mechanistic insight into drug resistance
Munmun Panda, Bijesh K. Biswal
Molecular Biology Reports
Published: Jul 2019
76 citations
76 citations
993 days before retraction
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
Rossella Loria, Valentina Laquintana, Giulia Bon et al. (15 authors)
Oncogene
Open Access
Published: Jul 2018
29 citations
29 citations
1358 days before retraction
MST1R/RON and EGFR in a complex with syndecans sustain carcinoma S-phase progression by preventing p38MAPK activation
DeannaLee M. Beauvais, Kristin Short, Noah A. Stueven et al. (9 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Jan 2018
2 citations
2 citations
1521 days before retraction
Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance
Anna Vert, Jessica Castro, Marc Ribó et al. (5 authors)
OncoTargets and Therapy
Open Access
Published: Jan 2018
17 citations
17 citations
1544 days before retraction
Laminin-511: a key regulator of breast cancer metastasis
Selda Star
Unknown Journal
Published: Jan 2018
1544 days before retraction
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition
Takuya Osada, Michael A. Morse, Amy Hobeika et al. (13 authors)
OncoImmunology
Open Access
Published: Apr 2017
24 citations
24 citations
1808 days before retraction
Dual-ligand α5β1 and α6β4 integrin targeting enhances gene delivery and selectivity to cancer cells
Rachel M. Levine, Efrosini Kokkoli
Journal of Controlled Release
Open Access
Published: Feb 2017
29 citations
29 citations
1862 days before retraction
The opposing roles of laminin-binding integrins in cancer
Veronika Ramovš, Lisa te Molder, Arnoud Sonnenberg
Matrix Biology
Published: Aug 2016
135 citations
135 citations
2039 days before retraction
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
Giulia Bon, Rossella Loria, Carla Azzurra Amoreo et al. (14 authors)
Oncotarget
Open Access
Published: Aug 2016
8 citations
8 citations
2044 days before retraction
Pancreatic cancer stem cell markers and exosomes - the incentive push
Sarah Heiler, Zhe Wang, Margot Zöller
World Journal of Gastroenterology
Open Access
Published: Jan 2016
87 citations
87 citations
2275 days before retraction
Exploring Critical Vehicle Parameters for the Design of Multitargeted Nanoparticles for Cancer Specific Gene Delivery
Rachel M. Levine
Unknown Journal
Published: Oct 2015
2367 days before retraction
Syndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the α3β1 Integrin Via Binding Sites in Their Ectodomains
Haiyao Wang, Haining Jin, Alan C. Rapraeger
Journal of Biological Chemistry
Open Access
Published: Sep 2015
66 citations
66 citations
2389 days before retraction
Clinical significance of the integrin α6β4 in human malignancies
Rachel L. Stewart, Kathleen L. O’Connor
Laboratory Investigation
Open Access
Published: Jun 2015
192 citations
192 citations
2461 days before retraction
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells
Rossella Loria, Giulia Bon, Valentina Perotti et al. (14 authors)
Oncotarget
Open Access
Published: Dec 2014
67 citations
67 citations
2654 days before retraction
β1 and β4 integrins: from breast development to clinical practice
Paola Nisticò, Francesca Di Modugno, Sheila Spada et al. (4 authors)
Breast Cancer Research
Open Access
Published: Oct 2014
65 citations
65 citations
2704 days before retraction
Cytoplasmic Domain Interactions of Syndecan-1 and Syndecan-4 with α6β4 Integrin Mediate Human Epidermal Growth Factor Receptor (HER1 and HER2)-dependent Motility and Survival
Haiyao Wang, Haining Jin, DeannaLee M. Beauvais et al. (4 authors)
Journal of Biological Chemistry
Open Access
Published: Sep 2014
59 citations
59 citations
2754 days before retraction
Integrins
Cuicui Sun, Xian‐Jun Qu, Zu‐Hua Gao
Anti-Cancer Drugs
Published: Jul 2014
32 citations
32 citations
2815 days before retraction
The impact of tumor stroma on drug response in breast cancer
Jürgen Dittmer, Benjamin Leyh
Seminars in Cancer Biology
Published: Jun 2014
98 citations
98 citations
2849 days before retraction
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
John M.S. Bartlett, Cassandra Brookes, Tammy Piper et al. (16 authors)
British Journal of Cancer
Open Access
Published: Oct 2013
6 citations
6 citations
3097 days before retraction
Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer
Stefan Werner, Sabrina Frey, Sabine Riethdorf et al. (12 authors)
Journal of Biological Chemistry
Open Access
Published: Jun 2013
118 citations
118 citations
3190 days before retraction
Role of β4 integrin in <i>HER-3</i>-negative, <i>K-RAS</i> wild-type metastatic colorectal tumors receiving cetuximab
Mario Scartozzi, Riccardo Giampieri, Cristian Loretelli et al. (12 authors)
Future Oncology
Published: Apr 2013
5 citations
5 citations
3255 days before retraction
Exploring the role of CD44 in tamoxifen resistant breast cancer
B. Baruah
Unknown Journal
Published: Jan 2013
3370 days before retraction
Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells
Valentina Folgiero, Selene E. Di Carlo, Giulia Bon et al. (13 authors)
Cell Death and Disease
Open Access
Published: Dec 2012
12 citations
12 citations
3396 days before retraction
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Karin Beelen, Wilbert Zwart, Sabine C. Linn
Nature Reviews Clinical Oncology
Published: Jul 2012
70 citations
70 citations
3531 days before retraction
Controlled Breast Cancer Microarrays for the Deconvolution of Cellular Multilayering and Density Effects upon Drug Responses
Maria Håkanson, Stefan Kӧbel, Matthias P. Lütolf et al. (6 authors)
PLoS ONE
Open Access
Published: Jun 2012
27 citations
27 citations
3556 days before retraction
Integrin Signaling in Cancer Cell Survival and Chemoresistance
Fawzi Aoudjit, Kristiina Vuori
Chemotherapy Research and Practice
Open Access
Published: Apr 2012
200 citations
200 citations
3635 days before retraction
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
Iain R. Hutcheson, Lindy Goddard, Denise Barrow et al. (8 authors)
Breast Cancer Research
Open Access
Published: Mar 2011
50 citations
50 citations
4032 days before retraction
Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance
Julia M.W. Gee, Robert I. Nicholson, Denise Barrow et al. (11 authors)
Hormone Molecular Biology and Clinical Investigation
Published: Mar 2011
9 citations
9 citations
4042 days before retraction
Engineered 3D models to study the cancer microenvironment as a determinant of drug response
Maria Håkanson
Unknown Journal
Published: Jan 2011
4101 days before retraction
Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells
Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. (7 authors)
Cancer Letters
Published: Dec 2010
17 citations
17 citations
4132 days before retraction
Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer
Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. (7 authors)
The Prostate
Published: Oct 2010
12 citations
12 citations
4179 days before retraction
ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells
Sheryl R. Krig, Joan Miller, Seth Frietze et al. (8 authors)
Oncogene
Open Access
Published: Jul 2010
64 citations
64 citations
4260 days before retraction
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne, Rachel Schiff
Annual Review of Medicine
Open Access
Published: Jan 2010
1120 citations
1120 citations
4441 days before retraction
Targeting<i>miR-205</i>in breast cancer
Hailong Wu, Yin‐Yuan Mo
Expert Opinion on Therapeutic Targets
Published: Oct 2009
67 citations
67 citations
4540 days before retraction
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads, Robert A. Gatenby, William S. Dalton
Nature reviews. Cancer
Published: Aug 2009
833 citations
833 citations
4600 days before retraction
Micro-SPECT/CT with <sup>111</sup>In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated <i>HER2</i> Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts
Kristin McLarty, Bart Cornelissen, Zhongli Cai et al. (7 authors)
Journal of Nuclear Medicine
Open Access
Published: Jul 2009
75 citations
75 citations
4634 days before retraction
Negative Regulation of β4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression
Giulia Bon, Selene E. Di Carlo, Valentina Folgiero et al. (12 authors)
Cancer Research
Open Access
Published: Jul 2009
51 citations
51 citations
4650 days before retraction
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
Birgit Schoeberl, Emily A. Pace, Jonathan B. Fitzgerald et al. (17 authors)
Science Signaling
Published: Jun 2009
366 citations
366 citations
4651 days before retraction
HER3 is required for the maintenance of neuregulin‐dependent and ‐independent attributes of malignant progression in prostate cancer cells
Marta Soler, Francesca Mancini, Óscar Meca‐Cortés et al. (10 authors)
International Journal of Cancer
Published: Jun 2009
44 citations
44 citations
4666 days before retraction
Loss of <i>Phosphatase and Tensin Homologue Deleted on Chromosome 10</i> Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
Todd W. Miller, Marianela Pérez-Torres, Archana Narasanna et al. (12 authors)
Cancer Research
Open Access
Published: May 2009
167 citations
167 citations
4699 days before retraction
Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis
Payaningal R. Somanath, Nikolay Malinin, Tatiana V. Byzova
Angiogenesis
Open Access
Published: Mar 2009
240 citations
240 citations
4766 days before retraction
Signal co-operation between integrins and other receptor systems
Charles Streuli, Nasreen Akhtar
Biochemical Journal
Open Access
Published: Feb 2009
304 citations
304 citations
4776 days before retraction
Adverse Features of Acquired Antihormone Resistance and Their Targeting
Stephen Hiscox, Nicola Jordan, L. Morgan et al. (7 authors)
Springer eBooks
Published: Jan 2009
1 citation
1 citation
4822 days before retraction
Quick Stats
Total Citations:
53
Years Since Retraction:
3.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025